Positive News SentimentPositive NewsNASDAQ:ASND Ascendis Pharma A/S (ASND) Stock Price, News & Analysis $194.27 +0.37 (+0.19%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$194.23 -0.04 (-0.02%) As of 08/29/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ascendis Pharma A/S Stock (NASDAQ:ASND) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ascendis Pharma A/S alerts:Sign Up Key Stats Today's Range$191.19▼$194.7550-Day Range$163.32▼$198.3252-Week Range$111.09▼$199.99Volume357,323 shsAverage Volume543,273 shsMarket Capitalization$11.89 billionP/E RatioN/ADividend YieldN/APrice Target$243.36Consensus RatingBuy Company Overview Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. Read More Ascendis Pharma A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreASND MarketRank™: Ascendis Pharma A/S scored higher than 68% of companies evaluated by MarketBeat, and ranked 326th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAscendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAscendis Pharma A/S has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ascendis Pharma A/S's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($4.34) to $0.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is -37.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is -37.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ascendis Pharma A/S's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.52% of the float of Ascendis Pharma A/S has been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Ascendis Pharma A/S has recently increased by 1.10%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.52% of the float of Ascendis Pharma A/S has been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Ascendis Pharma A/S has recently increased by 1.10%, indicating that investor sentiment is decreasing. News and Social Media4.2 / 5News Sentiment1.53 News SentimentAscendis Pharma A/S has a news sentiment score of 1.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Ascendis Pharma A/S this week, compared to 8 articles on an average week.Search Interest11 people have searched for ASND on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.MarketBeat Follows5 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Ascendis Pharma A/S's insider trading history. Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASND Stock News HeadlinesAscendis Pharma to Participate in the 2025 Wells Fargo Healthcare ConferenceAugust 28 at 6:36 PM | finance.yahoo.comAscendis Pharma to Participate in the 2025 Wells Fargo Healthcare ConferenceAugust 28 at 4:01 PM | globenewswire.comIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, and has now reached every AI company in America... including Nvidia, Microsoft, and Meta. | Altimetry (Ad)Ascendis: After Long Bull Run, New Commercial Challenges Suggest Rating DowngradeAugust 21, 2025 | seekingalpha.comAscendis Pharma price target raised to $260 from $254 at JPMorganAugust 20, 2025 | msn.comNew Forecasts: Here's What Analysts Think The Future Holds For Ascendis Pharma A/S (NASDAQ:ASND)August 16, 2025 | finance.yahoo.comAscendis Pharma A/S Q2 Earnings Call Highlights GrowthAugust 13, 2025 | msn.comAscendis Pharma A/S (NASDAQ:ASND) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comSee More Headlines ASND Stock Analysis - Frequently Asked Questions How have ASND shares performed this year? Ascendis Pharma A/S's stock was trading at $137.67 on January 1st, 2025. Since then, ASND stock has increased by 41.1% and is now trading at $194.27. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings results on Thursday, August, 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.49. The biotechnology company had revenue of $216.28 million for the quarter, compared to the consensus estimate of $163.17 million. Read the conference call transcript. When did Ascendis Pharma A/S IPO? Ascendis Pharma A/S (ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager. Who are Ascendis Pharma A/S's major shareholders? Top institutional investors of Ascendis Pharma A/S include Westfield Capital Management Co. LP (8.91%), Artisan Partners Limited Partnership (6.53%), Massachusetts Financial Services Co. MA (3.11%) and Perceptive Advisors LLC (1.58%). How do I buy shares of Ascendis Pharma A/S? Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD). Company Calendar Last Earnings8/07/2025Today8/29/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASND CIK1612042 Webwww.ascendispharma.com Phone(457) 022-2244Fax45-3694-4010Employees1,017Year FoundedN/APrice Target and Rating Average Price Target for Ascendis Pharma A/S$243.36 High Price Target$307.00 Low Price Target$153.00 Potential Upside/Downside+25.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($5.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$409.12 million Net Margins-54.94% Pretax Margin-53.33% Return on EquityN/A Return on Assets-24.31% Debt Debt-to-Equity RatioN/A Current Ratio1.02 Quick Ratio0.69 Sales & Book Value Annual Sales$393.54 million Price / Sales30.22 Cash FlowN/A Price / Cash FlowN/A Book Value($3.48) per share Price / Book-55.82Miscellaneous Outstanding Shares61,210,000Free Float36,727,000Market Cap$11.89 billion OptionableOptionable Beta0.41 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ASND) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.